Sido Muncul Valuation Multiples

Sido Muncul Overview

About Sido Muncul

PT Industri Jamu dan Farmasi Sido Muncul Tbk is biotechnology company that provides herbal medicine and pharmaceutical products. The company has three business segments, Herbal Medicine and supplement, Food and Beverage, and Pharmacy. The Herbal Medicine segment provides herbal supplements, while its Food and Beverage segment sells packaged foods, soft drinks, and candy and confectionary products. The Pharmacy segment sells pharmaceutical products such as Anacetine, a fever reducer, Berlosid, a medicine to reduce gastric pain, and Combicitrine, a medicine for bacterial removal. The company generates the majority of its revenue in Indonesia.

Founded

1975

HQ

Employees

4.4K

Website

sidomuncul.co.id

Sectors

Nutraceuticals & CosmeceuticalsBioTech

Financials (LTM)

Revenue: $244M

EBITDA: $99M

EV

$859M

Valuation Multiples

Multiples.vc

Start free trial

Sido Muncul Financials

Sido Muncul reported last 12-month revenue of $244M and EBITDA of $99M.

In the same LTM period, Sido Muncul generated $142M in gross profit, $99M in EBITDA, and $74M in net income.

Sido Muncul P&L

In the most recent fiscal year, Sido Muncul reported revenue of $244M and EBITDA of $98M.

Sido Muncul expects next 12-month revenue of XXX and NTM EBITDA of XXX

Sido Muncul Stock Performance

Sido Muncul has current market cap of $885M, and enterprise value of $859M.

Sido Muncul's stock price is $0.03.

Sido Muncul Valuation Multiples

Sido Muncul trades at 3.5x EV/Revenue multiple, and 8.7x EV/EBITDA.

Sido Muncul Financial Valuation Multiples

As of April 18, 2026, Sido Muncul has market cap of $885M and EV of $859M.

Equity research analysts estimate Sido Muncul's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sido Muncul has a P/E ratio of 12.0x.

Sido Muncul Margins & Growth Rates

Sido Muncul's revenue in the last 12 month grew by 3%.

Sido Muncul's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Sido Muncul's rule of 40 is 44% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sido Muncul's rule of X is 49% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Sido Muncul Public Comps

See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.

Sido Muncul M&A Activity

Sido Muncul acquired XXX companies to date.

Last acquisition by Sido Muncul was on XXXXXXXX, XXXXX. Sido Muncul acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Sido Muncul Investment Activity

Sido Muncul invested in XXX companies to date.

Sido Muncul made its latest investment on XXXXXXXX, XXXXX. Sido Muncul invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).